Literature DB >> 26208812

Extrahepatic manifestations of hepatitis C infection: navigating CHASM.

Amy C Sherman1, Kenneth E Sherman.   

Abstract

This article describes the importance of extrahepatic systemic manifestations of chronic hepatitis C virus (HCV) infection. While most HCV literature focuses on liver injury and fibrosis progression, a spectrum of systemic disease processes, collectively called C hepatitis-associated systemic manifestations (CHASMs), are present in a high proportion of infected persons. These include thyroid disease (Hashimoto's thyroiditis, Graves disease, and thyroid cancer), cardiovascular disease (atherosclerosis, carotid artery disease, and coronary artery disease), renal disease (MPGN and glomerulosclerosis), eye disease (Mooren's ulcers and sicca syndrome), skin disease (PCT, vasculitis, and lichen planus), lymphomas (NHL and splenic T-cell), and diabetes. Mechanistic understanding of how HCV leads to CHASM processes could lead to development of new interventions. The role of early HCV treatment and cure may result in preventive strategies for a variety of complex disease states. Key Points • Systemic extrahepatic complications of HCV comprise a spectrum of disease states in many organs and systems.• Effective treatment of HCV may reduce or eliminate some but not all of these systemic complications.• Further research into early treatment intervention as a prevention strategy for systemic disease is warranted.

Entities:  

Mesh:

Year:  2015        PMID: 26208812      PMCID: PMC4554601          DOI: 10.1007/s11904-015-0274-8

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  87 in total

Review 1.  Therapy for cryoglobulinemia secondary to hepatitis C virus: the need for tailored protocols and multiclinic studies.

Authors:  V Agnello
Journal:  J Rheumatol       Date:  2000-09       Impact factor: 4.666

Review 2.  Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights.

Authors:  Gül Bahtiyar; John J Shin; Ayse Aytaman; James R Sowers; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2004-06       Impact factor: 4.810

3.  Hepatitis C virus in patients with cryoglobulinemia type II.

Authors:  M Pascual; L Perrin; E Giostra; J A Schifferli
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

4.  Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient decrease in HCV RNA levels.

Authors:  M Furuta; M Kaito; E Gabazza; N Fujita; S Ishida; S Tamaki; R Ikeda; S Wakisawa; H Hayashi; S Watanabe; Y Adachi
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

5.  [Evolution of Sjögren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin].

Authors:  V Doffoël-Hantz; V Loustaud-Ratti; M Ramos-Casals; S Alain; H Bezanahary; E Liozon; A L Fauchais; E Vidal
Journal:  Rev Med Interne       Date:  2005-02       Impact factor: 0.728

6.  High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy.

Authors:  A Tran; J F Quaranta; S Benzaken; V Thiers; H T Chau; P Hastier; D Regnier; G Dreyfus; C Pradier; J L Sadoul
Journal:  Hepatology       Date:  1993-08       Impact factor: 17.425

7.  Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus.

Authors:  Thomas P Giordano; Louise Henderson; Ola Landgren; Elizabeth Y Chiao; Jennifer R Kramer; Hashem El-Serag; Eric A Engels
Journal:  JAMA       Date:  2007-05-09       Impact factor: 56.272

8.  True primary Sjögren's syndrome in a subset of patients with hepatitis C infection: a model linking chronic infection to chronic sialadenitis.

Authors:  Salvatore De Vita; Rosaria Damato; Ginevra De Marchi; Stefania Sacco; Gianfranco Ferraccioli
Journal:  Isr Med Assoc J       Date:  2002-12       Impact factor: 0.892

9.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

10.  Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection.

Authors:  Javier Bartolomé; Elena Rodríguez-Iñigo; Pedro Quadros; Sonia Vidal; Isabel Pascual-Miguelañez; José Antonio Rodríguez-Montes; Luis García-Sancho; Vicente Carreño
Journal:  J Med Virol       Date:  2008-09       Impact factor: 2.327

View more
  15 in total

Review 1.  Hepatitis C Virus, Inflammation, and Cellular Aging: Turning Back Time.

Authors:  Susanna Naggie
Journal:  Top Antivir Med       Date:  2017 Feb/Mar

Review 2.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

3.  MicroRNA 122 Affects both the Initiation and the Maintenance of Hepatitis C Virus Infections.

Authors:  Mamata Panigrahi; Patricia A Thibault; Joyce A Wilson
Journal:  J Virol       Date:  2021-12-15       Impact factor: 6.549

4.  Hepatitis C Virus Infection of Human Thyrocytes: Metabolic, Hormonal, and Immunological Implications.

Authors:  Sara Salehi Hammerstad; Jason T Blackard; Angela Lombardi; Randall P Owen; Erlinda Concepcion; Zhengzi Yi; Weijia Zhang; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

5.  Soluble CD163 Identifies Those at Risk for Increased Hepatic Inflammation & Fibrosis.

Authors:  Kenneth E Sherman; Heidi L Meeds; Susan D Rouster; Enass A Abdel-Hameed; Jacqueline Hernandez; Javier Tamargo; Jun Chen; Richard L Ehman; Marianna Baum
Journal:  Open Forum Infect Dis       Date:  2021-04-22       Impact factor: 3.835

6.  Internal driving factors leading to extrahepatic manifestation of the hepatitis C virus infection.

Authors:  Zhou-Yi Wu; Jian-Rui Li; Meng-Hao Huang; Jun-Jun Cheng; Hu Li; Jin-Hua Chen; Xiao-Qin Lv; Zong-Gen Peng; Jian-Dong Jiang
Journal:  Int J Mol Med       Date:  2017-10-05       Impact factor: 4.101

7.  A preliminary analysis of hepatitis C virus in pancreatic islet cells.

Authors:  Jason T Blackard; Ling Kong; Angela Lombardi; Dirk Homann; Sara Salehi Hammerstad; Yaron Tomer
Journal:  Virol J       Date:  2017-12-20       Impact factor: 4.099

Review 8.  Systemic manifestations of hepatitis C infection.

Authors:  Lydia Tang; Lauren Marcell; Shyam Kottilil
Journal:  Infect Agent Cancer       Date:  2016-05-23       Impact factor: 2.965

9.  Association of Sjögrens Syndrome in Patients with Chronic Hepatitis Virus Infection: A Population-Based Analysis.

Authors:  Chih-Ching Yeh; Wen-Chang Wang; Chien-Sheng Wu; Fung-Chang Sung; Chien-Tien Su; Ying-Hua Shieh; Shih-Ni Chang; Fu-Hsiung Su
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240

10.  Ocular Surface Disorders in a Group of Egyptian Children with End Stage Renal Failure on Dialysis: A Cross-Sectional Study.

Authors:  Mohamed Anbar; Ahmed R H Ahmed; Abdel-Azeem M El-Mazary; Ramadan A Mahmoud
Journal:  J Ophthalmol       Date:  2016-01-28       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.